EUCTR2004-001658-10-IT进行中（未招募）不适用
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor-selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks.
TIBOTEC PHARMACEUTICALS LTD.0 个研究点开始时间: 2005年9月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized to an active control arm of any sponsor-selected TMC125 trial and either virologically failed or completed the entire treatment period. - N/AHIV-1 infectionEUCTR2004-001658-10-ESTibotec Pharmaceuticals Limited60
进行中（未招募）
不适用
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks. - N/AHIV-1 infectionEUCTR2004-001658-10-BETibotec Pharmaceuticals Limited170
进行中（未招募）
不适用
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks. - N/AHIV-1 infectionEUCTR2004-001658-10-PTTibotec Pharmaceuticals Limited170
进行中（未招募）
1 期
An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks. - N/AHIV-1 infectionEUCTR2004-001658-10-GBTibotec Pharmaceuticals Limited170
进行中（未招募）
不适用
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. - N/AHIV-1 InfectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2005-000712-27-DETibotec Pharmaceuticals Limited300